3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
44
Burkitt Lymphoma
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Recurrence
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Smoldering Multiple Myeloma
2
Rectal Neoplasms
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia
2
Down Syndrome
2
beta-Thalassemia
1
Waldenstrom Macroglobulinemia
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thalassemia
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Plasmacytoma
1
Plasmablastic Lymphoma
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Interventions
Etoposide
3
daratumumab
2
Vincristine
2
Prednisone
2
Doxorubicin
2
Cyclophosphamide
2
prednylidene
1
pomalidomide
1
deltacortene
1
carmustine, poliferprosan 20 drug combination
1
Rituximab
1
Peripheral Blood Stem Cell Transplantation
1
Melphalan
1
Dexamethasone
1
Cytarabine
1
Carmustine
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmablastic Lymphoma
×
Dexamethasone
×
30 days
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled